foxo4 dri senolytic 2023 2024 ES2 rapidly destroys TP53-FOXO4 foci leading to TP53 mediated FOXO4-DRI: The Senolytic Peptide That

Who Typically Uses Peptide Therapy

[DOI] [PubMed] [Google Scholar] Stupnisek M, Franjic S, Drmic D, et al

This molecule is also expressed on tumor cells, mature innate immune cells such as macrophages and mast cells, and on adaptive immune cells such as T-cells [98]

98 g/wk (%) 60 (24.6) 157 (18.6) .041 Current smoker (%) 49 (20.7) 168 (20.4) .936 Cardiovascular disease (%) 45 (18.2) 119 (13.8) .082 Diabetic retinopathy (%) 44 (23.3) 128 (19.6) .265 Systolic BP, mm Hg 130.1 12.6 128.4 12.3 .047 Diastolic BP, mm Hg 78.010.1 76.99.4 .090 Hypertension (%) 179 (72.5) 574 (66.7) .085 Anemia (%) 48 (19.4) 117 (13.6) .022 Neuropathy (%) 67 (28.0) 179 (21.4) .031 Fasting glucose, mg/dL 139.4 36.6 138.7 37.3 .791 Hemoglobin A1c (%) 7.1 0.9 7.2 1.0 .167 HOMA-IR 1.1 0.9 1.2 2.5 .763 Hemoglobin, g/dL 13.6 1.6 13.8 1.7 .053 MCV, fL 90.44.7 91.7 29.9 .504 Total cholesterol, mg/dL 144.5 27.0 146.5 25.7 .285 Triglyceride, mg/dL 138.8 70.8 137.5 70.6 .800 HDL-cholesterol, mg/dL 45.6 10.5 46.0 10.8 .612 LDL-cholesterol, mg/dL 76.4 24.3 77.6 21.9 .466 AST, IU/L 25.4 10.7 28.2 12.7 .001 ALT, IU/L 23.4 13.4 28.2 16.5 2